Our findings suggest that the FAM molecular subtype biomarkers ACSL5, ALOX5AP, CD1D, CD74, IL4I1, and TBXAS1 can be independent predictors of prognosis and immunotherapy response in CM patients. The gene discussed is IL4I1; the disease is cutaneous mastocytosis.